The Arizona Emergency Medicine Research Center (AEMRC) Tucson includes research collaborations that bridge multiple departments and colleges not only in Arizona, but in other states as well. Kurt Denninghoff, MD directs a clinical research platform that has successfully set new standards of excellence for process innovation and trial enrollment. Clinical research nurses are now deployed 24 hours a day, seven days a week at both academic Emergency Departments in Tucson (Banner - University Medical Center Tucson and South campuses) screening 100 percent of the more than 110,000 patients we serve annually for potential inclusion into the nation’s leading clinical trials. Current projects include:
•Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) is an NIH-funded trial, administered by the Neurological Emergencies Treatment Trials program (NETT). The NETT is a 17-site nationwide network created to conduct large clinical trials to reduce the burden of very acute injuries and illnesses affecting the brain, spinal cord and peripheral nervous system. This network provides the basis for conducting efficient studies in these environments. The NETT is coordinated by the University of Michigan under the leadership of Dr. William Barsan. In Arizona, this study is being spearheaded by Dr. Kurt Denninghoff and Dr. Kendra Drake of the University of Arizona.
•Stroke Hyperglycemia Insulin Network Effort (SHINE) is studying the effects of controlling elevated blood sugar levels in stroke patients compared to utilizing other methods to control blood sugar. The clinical trial, led by Drs. Drake and Denninghoff, is running at the University and South Campuses of Banner University Medical Center.
•Application of Transcriptional Signatures for Diagnosis of Febrile Infants within the PECARN Network (BioSigs) is running at the Banner University Medical Center. Dr Aaron Leech, MD is the principal investigator. The study’s ultimate goal is to create a test that will rapidly determine if an infection is bacterial or non-bacterial, thereby sparing many newborns unnecessary invasive procedures such as lumbar punctures, overuse of antibiotics and hospitalizations.
•MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE) a clinical trial, led by Dr. Kurt Denninghoff, is running at the Banner University Medical Center. The primary objective of the study is to demonstrate that low risk pulmonary embolism (PE) patients who are discharged from the ED to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or VTE events through Day 30 compared to patients who are treated with initial hospitalization and standard-of-care.
Other research proposals submitted and awaiting funding. (fingers crossed)